Navigation Links
OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Date:11/23/2012

SUNNYVALE, Calif. and NEW YORK, Nov. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that OneMedPlace's Research Division has released an update to its previous research report on Amarantus Biosciences, highlighting recently announced positive ischemic heart disease (myocardial infarction, heart attack) efficacy data for MANF in animals. The updated research report focuses on the mechanisms of action by which MANF functions to protect heart cells under conditions that simulate ischemic heart disease in animals. The updated research report from OneMedPlace Research can be found online at http://www.onemedplace.com/reports/Amarantus_Research_Update_112012.pdf.

The report states: "The results showed that MANF has a robust ability to protect the heart; during episodes of ischemia-reperfusion injury, hearts treated with MANF had 40% less total area of cell death as compared control hearts that did not receive treatment. These data serve as strong evidence that positions MANF as a potential breakthrough therapeutic treatment for ischemic heart conditions. This study adds to an accumulating body of research that all corroborate the therapeutic effects of MANF. Since its original discovery in 2003, MANF has been the subject of over 20 independent studies that identify its
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
2. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
3. eCareSoft Releases eCS Cirrus™
4. AtheroNova Releases 2011 Financial Results
5. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
6. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
7. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
8. Happtique Releases Draft App Certification Program Standards For Public Comment
9. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
10. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading professional ... In his new role as treasurer, Dr. Hill also ... a voice in furthering the mission of ASRM. , ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... (Amex: PTN ) announced today financial results for ... net loss of $247,000, or $0.00,per basic and diluted ... a net loss of $8.4 million, or ($0.12) per ... Total revenues for the quarter ended,September 30, 2007 were ...
... 9 at 8:00 a.m. PST -, SAN ... HALO ), a biopharmaceutical company developing and commercializing,products ... for the three and nine months ended September ... the complexities of the,extracellular matrix provide a number ...
... 8 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today reported ... 2007. Net loss for the quarter and nine months ... $0.26 per share and $0.46 per share,compared to a net ... per share, in the same periods last year. Revenues ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 2Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 3Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 4Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 5Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 6Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 CIE San ... that provides the connective tissue that enhances care coordination among ... share client-level information; earned a second $1 million grant from ... aging in community and; will be recognized as a "Live ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... biological weapons are created equal. They are separated into ... the scariest: They are easy to spread, kill effectively ... system. One of these worrisome organisms is anthrax, which ... But work in Vince Fischetti's laboratory at Rockefeller University ...
... National Institute of Allergy and Infectious Diseases (NIAID), ... today announced that enrollment into a large international ... drug treatment guided by levels of CD4+ cells ... patients receiving episodic therapy had twice the risk ...
... Scientists at Karolinska Institutet in Sweden have helped to ... vaccination agent against growing cancer tumours. Although the results ... to new methods of treating metastases. , The results ... scientific journal Nature Medicine, and represent the collaborative efforts ...
Cached Biology News:Newly discovered protein kills anthrax bacteria by exploding their cell walls 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 4
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Phospho-PERK (Thr980) Antibody...
Biology Products: